Latest stories on BTAI
Teva’s (TEVA) $125 Million BioXcel Bid Offers Upside, but FDA and Auction Risks Remain
Yahoo Finance58 · neutralm&a
BioXcel Therapeutics, Inc. (BTAI) files 8-K
SEC 8-K50 · neutralgeneral
Teva Pharmaceuticals to acquire BioXcel assets for up to $125m
Yahoo Top63 · neutralm&a
Teva Pharmaceuticals to acquire BioXcel assets for up to $125m
Yahoo Top63 · neutralm&a
BioXcel Therapeutics Initiates Chapter 11 and Sale Process
TipRanks12 · bearishgeneral
Teva unit bids to acquire neuroscience product from BioXcel Therapeutics
The Fly63 · neutralm&a
BioXcel files for Chapter 11, will sell assets to Teva
Seeking Alpha18 · bearishgeneral
BioXcel Therapeutics enters asset sale agreement with Teva
The Fly58 · neutralm&a
BioXcel Therapeutics, Inc. (BTAI) files 8-K
SEC 8-K50 · neutralgeneral
BioXcel Therapeutics Enters Into Asset Sale Agreement with Teva Pharmaceuticals
StockTitan58 · neutralm&a
BioXcel Therapeutics Amends Credit Agreement Amid Liquidity Strain
TipRanks34 · bearishgeneral
BioXcel Therapeutics, Inc. (BTAI) files 8-K
SEC 8-K50 · neutralgeneral
BioXcel Therapeutics Amends Credit Agreement, Extends Financing Deadline
TipRanks55 · neutralgeneral
BioXcel Therapeutics, Inc. (BTAI) files 8-K
SEC 8-K50 · neutralgeneral
BioXcel Therapeutics Amends Credit Agreement, Eases Liquidity Terms
TipRanks56 · neutralgeneral
BioXcel Therapeutics, Inc. (BTAI) files 8-K
SEC 8-K50 · neutralgeneral
BioXcel’s BXCL501 Agitation Study Completion: What Investors Should Watch Next
TipRanks56 · neutralproduct/pr
BioXcel Therapeutics Amends Credit Agreement, Extends Debt Deadline
TipRanks55 · neutralgeneral
BioXcel Therapeutics, Inc. (BTAI) files 8-K
SEC 8-K50 · neutralgeneral
BioXcel Therapeutics, Inc. (BTAI) files 8-K
SEC 8-K50 · neutralgeneral
BTAI: [144] BioXcel Therapeutics, Inc. SEC Filing
StockTitan SEC50 · neutralgeneral
BioXcel Therapeutics GAAP EPS of -$0.54 misses by $0.06, revenue of $0.21M misses by $0.17M
Seeking Alpha34 · bearishearnings